Abbott Laboratories vs. Ardelyx, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABT | ARDX | |
|---|---|---|
| Market Cap | $186.55 billion | $996.75 million |
| Revenue (TTM) | $46.59 billion | $450.89 million |
| Net Income (TTM) | $5.42 billion | $-55,702,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | ARDX | |
|---|---|---|
| P/E Ratio | 35.15 | — |
| Price / Book | 3.60 | 6.69 |
| Price / Sales | 4.00 | 2.21 |
ABT and ARDX split the valuation factors evenly.
Profitability
| ABT | ARDX | |
|---|---|---|
| Net Margin | 11.65% | -12.35% |
| Return on Equity | 10.48% | -37.38% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | ARDX | |
|---|---|---|
| Dividend Yield | 2.32% | — |
| Payout Ratio | 81.55 | — |
ABT and ARDX split the dividend factors evenly.
Risk & Sentiment
| ABT | ARDX | |
|---|---|---|
| Short Interest | 0.57% | 0.76% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, ARDX overview, ARDX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.